{
    "clinical_study": {
        "@rank": "149580", 
        "arm_group": [
            {
                "arm_group_label": "RO6811135", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, double-blind, placebo-controlled, multiple ascending dose study will\n      evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6811135 in\n      patients with type 2 diabetes mellitus. Patients will be randomized to receive either\n      RO6811135 or placebo daily for 2 weeks, with a follow-up examination 2 to 3 weeks after the\n      last dose of study drug."
        }, 
        "brief_title": "A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, 18 to 65 years of age, inclusive\n\n          -  Type 2 diabetes mellitus according to WHO criteria diagnosed for at least 3 months\n             prior to screening\n\n          -  On stable dose of metformin for at least 2 months prior to screening\n\n          -  Fasting plasma glucose during the screening period </= 240 mg/dL\n\n          -  Hemoglobin A1c (HbA1c) levels at screening >/= 6.5% and </= 10.5%\n\n          -  Evidence of insulin secretory capacity at screening\n\n          -  Body mass index (BMI) 27 to 42 kg/m2, inclusive\n\n          -  Females of child-bearing potential and males with female partners of child-bearing\n             potential must agree to use effective contraception as defined by protocol\n\n        Exclusion Criteria:\n\n          -  Type 1 diabetes\n\n          -  Acquired or secondary forms of diabetes such as those resulting from pancreatic\n             surgery/injury, cystic fibrosis related diabetes\n\n          -  History of acute metabolic complications such as diabetic ketoacidosis or state of\n             hyperosmolar hyperglycemia\n\n          -  Evidence or history of clinically significant diabetic complications such as\n             clinically severe diabetic peripheral neuropathy, clinically significant nephropathy\n             as judged by the investigator, or pre-proliferative/proliferative diabetic\n             retinopathy as judged by the investigator\n\n          -  History of severe symptomatic hypoglycemia (requiring assistances of a third party)\n             within 6 months prior to screening\n\n          -  History or presence of clinically significant concomitant disease or disorder\n\n          -  Hemoglobin level below the lower limit of reference range at screening\n\n          -  Pregnant or lactating women\n\n          -  History of anaphylaxis or severe systemic hypersensitivity or allergic reactions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789788", 
            "org_study_id": "BP28436"
        }, 
        "intervention": [
            {
                "arm_group_label": "RO6811135", 
                "description": "multiple ascending doses", 
                "intervention_name": "RO6811135", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo, multiple doses", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91911"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45227"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Patients With Type 2 Diabetes Mellitus.", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 14"
            }, 
            {
                "measure": "Pharmacodynamics of RO681135: Blood analysis", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}